Sutro Biopharma (STRO) FCF Margin (2017 - 2025)
Sutro Biopharma's (STRO) quarterly FCF Margin came in at 399.64% in Q4 2025, up 7562.0% year-on-year from 5.22% in Q4 2024, and down 1.31% quarter-over-quarter from 394.47% in Q3 2025.
Sutro Biopharma (STRO) FCF Margin (2017 - 2025) Analysis & Trends
Sutro Biopharma has disclosed FCF Margin across 9 years of filings, most recently posting 399.64% for Q4 2025.
- FCF Margin for Q4 2025 came in at 399.64%, up 7562.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 206.73% (up 14832.0% YoY), and the FY2025 annual result was 172.95%, up 13686.0% from the prior year.
- FCF Margin came in at 399.64% for Q4 2025 at Sutro Biopharma, down from 394.47% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 269.74% in Q3 2022 to a low of 1211.53% in Q1 2025.
- The 5-year median for FCF Margin is 322.16% (2022), against an average of 310.65%.
- Across the five-year window, FCF Margin soared 69027 bps in 2022 and sank 71040 bps in 2025, its largest moves.
- Sutro Biopharma's FCF Margin stood at 86.01% in 2021, then slumped by 303 bps to 346.93% in 2022, then surged by 104 bps to 14.71% in 2023, then tumbled by 3330 bps to 475.26% in 2024, then increased by 16 bps to 399.64% in 2025.
- The last three FCF Margin figures came in at 399.64% (Q4 2025), 394.47% (Q3 2025), and 68.36% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Sutro Biopharma | 252.04 Mn | 252.04 Mn | - | -399.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -399.64% |
| Sep 30, 2025 | -394.47% |
| Jun 30, 2025 | -68.36% |
| Mar 31, 2025 | -1,211.53% |
| Dec 31, 2024 | -475.26% |
| Sep 30, 2024 | -779.61% |
| Jun 30, 2024 | 54.93% |
| Mar 31, 2024 | -501.13% |
| Dec 31, 2023 | 14.71% |
| Sep 30, 2023 | -214.10% |
| Jun 30, 2023 | -297.40% |
| Mar 31, 2023 | -484.16% |
| Dec 31, 2022 | -346.93% |
| Sep 30, 2022 | 269.74% |
| Jun 30, 2022 | -21.56% |
| Mar 31, 2022 | -612.79% |
| Dec 31, 2021 | -86.01% |
| Sep 30, 2021 | -420.52% |
| Jun 30, 2021 | -15.20% |
| Mar 31, 2021 | -223.78% |